Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

SCT Licenses Exclusive Rights to Clinical Cancer Stem Cell Program

Published: Friday, April 19, 2013
Last Updated: Friday, April 19, 2013
Bookmark and Share
Corporate refocusing mission completed.

Stem Cell Therapeutics Corp. has announced the execution of a definitive license agreement with University Health Network ("UHN"), Toronto, Canada.

The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics ("SCT") with exclusive worldwide rights to an innovative clinical cancer stem cell program.

As announced on November 6, 2012, the technology licensed by SCT is based on Dr. Aaron Schimmer's discovery that an FDA-approved antibiotic, tigecycline, selectively targets leukemia cells and leukemic stem cells by inhibiting mitochondrial protein synthesis and thus shutting down the cells energy supply.

A Phase I multicenter dose- escalation clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) is nearing completion and data are expected this summer.

Dr. Schimmer will join Dr. John Dick as a scientific advisor to SCT. Furthermore, a clinical advisory board, chaired by Dr. Schimmer, will be assembled in the near term to guide and assist in the future development of the program.

"Using tigecycline to eradicate cancer stem cells, which are resistant to conventional chemotherapy and believed to be responsible for disease relapse, is an innovative and potentially curative approach to the treatment of AML," commented Dr. Bob Uger, SCT's Chief Scientific Officer.

Dr. Uger continued, "This program will provide the foundation for further research into mitochondrion-targeting therapies, an area that is of substantial interest to the scientific community."

The newly acquired tigecycline program complements SCT's other cancer stem cell program, SIRPaFc. The latter is an antibody-like Fc fusion protein that targets the CD47 protein with high affinity, facilitating the elimination of cancer cells and cancer stem cells by the patient's own immune system.

This program is at a preclinical stage and IND-enabling studies are expected to start pending the conclusion of an ongoing pharmacokinetic and safety study.

"We use two distinctly different approaches to target cancer stem cell in these programs. Tigecycline is a repurposed small molecule aimed at an intracellular metabolic target, while SIRPaFc is a novel biologic targeting an extracellular immunoregulatory pathway," remarked SCT's Chief Executive Officer, Dr. Niclas Stiernholm.

Dr. Stiernholm continued, "In our quest to become a Canadian cancer stem cell powerhouse with a diverse arsenal of product candidates, we are now assessing other opportunities and expect to add new collaborations and projects in due course."

"The conclusion of our recent financing, followed by the acquisition of Trillium and the licensing of the tigecycline technology completes my task of refocusing and reinvigorating the company," added David Allan.

Allan continued, "The appointment of Dr. Stiernholm as CEO of SCT now permits me to become non-executive chairman, a role in which I look forward to supporting the new management team, particularly assisting with the company's activities and visibility in the capital markets."

The initial consideration of $1.6 million for the UHN License is to be satisfied by the issuance of 5,028,571 SCT common shares and 1,600,000 SCT common share purchase warrants to UHN and MaRS Innovation, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.

Additional consideration under the UHN License includes an annual license maintenance fee and development milestones.

The securities issued by the Corporation will be subject to a statutory four-month hold period from the date of their issuance.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT Changes its Name to Trillium Therapeutics Inc.
Company has filed articles of amalgamation to merge with Trillium Therapeutics.
Tuesday, June 03, 2014
SCT to Provide Update on CD47 Program at the 2014 AACR Annual Meeting
Announcing a key difference between SIRPaFc and other CD47-blocking agents.
Friday, April 04, 2014
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.
Friday, December 20, 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation
Company receives drug designation for the use of tigecycline to treat AML.
Friday, November 01, 2013
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
SCT Announces Agreement with Trillium for Merger
Continuing Stem Cell Therapeutics' commitment to expansion.
Wednesday, February 06, 2013
Stem Cell Therapeutics Announces Agreement with UHN and MaRS Innovation
Building on the continued strength of Canadian stem cell research.
Thursday, November 08, 2012
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos